GlassScriptPhysician profile
Tinna P King
NPI 1932201092
$1,235.54
in general payments reported to CMS, 2019-2025
22 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.13 · 2020: $71.32 · 2021: $206 · 2022: $247 · 2023: $201 · 2024: $247 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.28 | 2019-2023 | Mounjaro |
| Abbvie INC. | $162.77 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $157.85 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $106.67 | 2024 | Quviviq |
| Novo Nordisk INC | $88.10 | 2023-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $67.53 | 2022 | |
| Amgen INC. | $63.03 | 2020-2025 | Otezla, Repatha |
| Pfizer INC. | $56.53 | 2023-2025 | |
| Daiichi Sankyo INC. | $54.26 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.10 | 2021-2022 | |
| Globus Medical, INC. | $23.03 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $20.58 | 2024 | Voquezna |
| Medicomp INC | $19.65 | 2023 | Telepatch Cardiac Monitor |
| Sanofi-Aventis U.S. LLC | $16.56 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.69 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $15.61 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $14.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.39 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.12 | 2020 | |
| Optos, INC. | $12.88 | 2020 | |
| Vyera Pharmaceuticals, LLC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tinna King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.